FDA approves pediatric use of Protalix drug
Following the announcement of the most recent FDA approval at the end of last week, shares of Protalix rose by a combined 7.9%.
Protalix Biotherapeutics has received expanded permission from the U.S. Food and Drug Administration to market its medication for the treatment of Gaucher’s disease, so that it can now be administered not only to adults but also to children. The move by the FDA follows clinical trials with the drug, Elelyso, among youngsters.
Like us on Facebook and get articles directly in your news feed